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Abstract Myoblast transfer therapy has been extensively
studied for a wide range of clinical applications, such as
tissue engineering for muscular loss, cardiac surgery or
Duchenne Muscular Dystrophy treatment. However, this
approach has been hindered by numerous limitations,
including early myoblast death after injection and specific
immune response after transplantation with allogenic
cells. Different cell sources have been analyzed to over-
come some of these limitations. The object of our study
was to investigate the growth potential, characterization
and integration in vivo of human primary fetal skeletal
muscle cells. These data together show the potential for
the creation of a cell bank to be used as a cell source for
muscle cell therapy and tissue engineering. For this pur-
pose, we developed primary muscular cell cultures from
biopsies of human male thigh muscle from a 16-week-old
fetus and from donors of 13 and 30 years old. We show
that fetal myogenic cells can be successfully isolated and
expanded in vitro from human fetal muscle biopsies, and
that fetal cells have higher growth capacities when com-
pared to young and adult cells. We confirm lineage
specificity by comparing fetal muscle cells to fetal skin
and bone cells in vitro by immunohistochemistry with
desmin and 5.1H11 antibodies. For the feasibility of the
cell bank, we ensured that fetal muscle cells retained
intrinsic characteristics after 5 years cryopreservation.
Finally, human fetal muscle cells marked with PKH26
were injected in normal C57BL/6 mice and were found to
be present up to 4 days. In conclusion we estimate that a
human fetal skeletal muscle cell bank can be created for
potential muscle cell therapy and tissue engineering.
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Introduction
Over the past years, myoblast transfer therapy or skeletal
myoblast transplantation has emerged as a potential
therapeutic option for the treatment of muscular dystro-
phies [1–4], the repair of infarcted myocardium [5] and
the regeneration of muscular loss [6]. The capacity of
skeletal myoblasts to restore dystrophin expression in
dystrophic recipients [7, 8] or engraft into infarction scars
[9] was demonstrated in several animal models, such as
mice, dogs and primates [10–13]. However, the effec-
tiveness of these techniques is hindered by numerous
limitations, including minimal distribution of cells after
injection [14], immune rejection [15] and poor cell sur-
vival [16–23]. A major limitation of cell transplantation
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remains death of the grafted cells. Up to 90% of these cell
types have been reported to be killed over the first 48 h
following their implantation [24, 25]. This major loss of
grafted cells is likely to seriously hamper the efficacy of
the procedure, as the functional benefit expected from
myoblast transplantation seems closely related to the
number of injected myoblasts [26]. Efforts have been
made to improve cell survival, either by changing
immunosuppressive or anti-inflammatory agents [27–29],
changing the cell source [30] and pretreatment of cells
[31] or by improving purification of specific cells popu-
lations [32–35].
Stem cells have raised the hope of scientists as they
have high self-renewal capacity and can generate multiple
cell lineages [36]. For muscular therapies, they have been
isolated not only from muscle [37] but also from many
tissues including bone marrow [38], amniotic fluid [39]
and umbilical cord blood [40]. Although widely distrib-
uted, stem cells represent only a small fraction of a tissue
cell population, and they require an extensive in vitro
expansion technique, and cultures of stem cells are usu-
ally technically very demanding. Only Atala’s group has
been able to establish consistent stem cell cultures without
the use of a feeder layer [41]. Nonetheless, many growth
factors are still necessary to direct the cell type, and large
expansion of these cells is not feasible [42]. Unlike stem
cells, fetal cells are differentiated cells with high expan-
sion and regeneration and low immunogenic properties
[43, 44]. They can be isolated from fetal tissues, which
follow the embryonic stage of 9 weeks of development.
Fetal cells are mature, fully differentiated cells and
capable of proliferating rapidly [45, 46] and have a higher
resistance to oxydatif stress than adult cells [47]. More-
over, fetal tissue is not easily rejected by the recipient due
to the low levels of histocompatibility antigens [43, 48,
49]. Fetal tissue is used for transplantation in adults to
treat Parkinson’s [50] or Huntington’s disease [51] with
fetal neurons, and human fetal pancreas has been trans-
planted in diabetic patients [52]. Applications of fetal cell
therapy are also of interest in the orthopedic area, where
human fetal bone cells were shown to have high prolif-
eration and differentiation ability and could be used as a
source of cells for bone tissue-engineering [53, 54].
Recently, biological bandages composed of fetal skin
fibroblasts improve skin regeneration in second- and third-
degree burned children [45, 47]. A highly consistent fetal
skin cell bank was created with which it was possible to
produce more than 270 million skin constructs for thera-
peutic use from one organ donation [47, 55].
In this study, we estimate the feasibility for the creation
of a human fetal skeletal muscle cell bank for potential
muscle cell therapy applications. We show that myogenic
cells can be successfully isolated and expanded in vitro
from human fetal and adult muscle biopsies and that fetal
cells have higher growth capacities. Human fetal skeletal
muscle cells were implanted in immunocompetent
C57BL/6 mice to assess cellular survival at 1 and 4 days
after injection.
Materials and methods
Muscle biopsies and cell culture
Two human fetal skeletal muscle biopsies (15 and
16 weeks), one fetal skin biopsy (14 weeks) and one fetal
bone biopsy (16 weeks) were obtained after pregnancy
termination with written, informed consent and approval
of the local Medical School Ethics Committee in the
Department of Obstetrics in Lausanne University Hospi-
tal. Skeletal muscle samples from adult donors (13 and
30 years) were obtained during surgery of the thighs, also
with written, informed consent and approval from the
Medical School Ethics Committee. All the muscle sam-
ples, measuring 1 cm3, were obtained from thigh muscle
for each patient. Primary cultures of fetal skin cells and
fetal bone cells were developed as described previously
[45, 47, 56].
Primary muscle cultures were established for all sam-
ples. Each biopsy was rinsed in phosphate-buffered saline
(PBS 1·) containing penicillin (100 U/ml) and strepto-
mycin (100 U/ml) (Gibco BRL, Life Technologies, Grand
Island, NY, USA). Then, muscle tissues were digested in
2.3 mg/ml type I collagenase (Gibco BRL) in Dulbecco’s
Modified Eagles Medium (DMEM, Gibco BRL) at 37C
for 1 h. After digestion, muscle fibers were dissociated
with a 1 ml pipette, and transferred into a fresh medium
consisting of DMEM containing 10% fetal bovine serum
(FBS, Gibco BRL). Cells were grown at 37C in a
humidified atmosphere with 90% air/5% CO2. Once the
cells reached 80% confluency, they were trypsinized
(EDTA and trypsin solution, Gibco BRL) and expanded in
T80 Falcon tissue culture flasks. When expanded cells
reached 80% confluency, they were trypsinized and cen-
trifuged at 1,000g for 15 min and resuspended in a freezing
solution of DMEM (5 ml) + FCS (4 ml) + DMSO (1 ml,
Fluka) and frozen in 1 ml aliquots (1–2 million cells) at
–80C in NalgeneTM Cryo 1C Freezing Container’s
(Nalgene) to achieve a –1C/min rate of cooling and
freezing curve. After 24 h, cells were transferred to liquid
nitrogen for longer storage. A second round of expansion
was performed and cells stored at the same conditions at
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passage 2. Cells were thawed for different experiments and
used between passages 2 to 4.
Growth curves
Fetal (16 weeks), young (13 years) and old (30 years)
muscle cells were thawed, expanded and seeded at
2.5 · 103 cell in 6 well culture dishes (4 cm diameter). At
each time point, cells were detached from culture dishes
with 1 ml of trypsin/EDTA (Gibco BRL), the reaction was
stopped by the addition of culture medium; cell suspension
was centrifuged at 1,000g for 5 min and counted in
triplicate.
Fetal muscle cells (15 weeks), fetal bone cells
(16 weeks) and fetal skin fibroblast cells (14 weeks) were
thawed expanded and seeded at 1 · 104 cell in 6 cm
diameter dishes in triplicate. At each time point, cells were
detached from culture dishes with 1 ml of trypsin/EDTA
(Gibco BRL), and the reaction was stopped by the addition
of culture medium. Cell suspension was centrifuged at
1,000g for 5 min, and cells were counted in triplicate.
Immunohistochemistry
Cells were grown on round glass slides (1 cm in diame-
ter) and when they reached 80–90% confluency they were
fixed with acetone for 10 min at room temperature. Slides
were washed in PBS 1· and incubated with normal goat
serum (NGS, DAKO, Denmark) for 30 min at room
temperature to block non-specific binding sites. Tissue
sections were then incubated for 30 min at room tem-
perature with an anti-desmin antibody (clone D33,
DAKO, Denmark, 1:100) or the 5.1H11 monoclonal
antibody, obtained from the Developmental Studies
Hybridoma Bank (1:1,000, the University of Iowa, Iowa
City, USA). This monoclonal antibody 5.1H11 has been
shown to specifically recognize a surface antigen (Neural
Cell Adhesion Molecule, NCAM) on human myogenic
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Fig. 1 Top. Cell growth of
human skeletal muscle primary
cells as a function of time for
fetal, young and old starting
with 260 cells/cm2 for each
sample. Each data point is
represented by the average cell
number from three culture
plates. Bottom 5.1H11 and
desmin immunohistochemical
staining of fetal, young and
adult skeletal muscle primary
cell culture. ·50 magnification
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cells [57]. Following washes in PBS 1·, sections were
incubated with biotinylated secondary anti-mouse anti-
body (Vector, Burlingame, CA, USA; 1:200) for 30 min
at room temperature. Samples were then incubated for
30 min at room temperature in Vectastain ABC1 (Vector,
Burlingame, CA, USA), a solution of a complex of avi-
din/biotin peroxydase, as described by the company.
Following this incubation, tissue sections were washed
with PBS 1· and incubated with 0.5 mg/ml 3,30-diam-
inobenzidine with 0.32 ll 30% H2O2 added just before an
incubation of 1–2 min. All samples were treated simul-
taneously. The samples were then washed for 5 min under
running water, counterstained with Papanicolaou (Harris’
hematoxylin solution), dehydrated and mounted with
Merckoglas1 (Merck). Sections stained for each antibody
were analyzed with a Leica DFC280 videoimaging
system.
Cell labeling for animal experimentation
Fetal muscle cells (16 weeks) were thawed and expanded
in cell culture. Cell viability was monitored, and desmin
immunohistochemistry was performed to ensure the quality
of the cells. Fetal muscle cells were labeled with the
PKH26 Red Fluorescent Cell Linker Kit (Sigma-Chemi-
cals, St. Louis, MO, USA) as follows: 2 · 106 were
washed once in serum-free medium (DMEM) and sus-
pended in 250 ll of Diluent solution C (included in the
PKH26 labeling kit). A volume of 250 ll of PKH26 at
2 · 10–3 M in Diluent C was added, mixed, and cells were
incubated for 5 min at room temperature. The labeling
reaction was terminated by adding 500 ll of FBS. The cell
suspension was centrifuged, washed three times with
DMEM, 10% FBS. The concentration of fetal muscle
cell suspension labeled with PKH26 was adjusted to
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Fig. 2 Top. Cell growth of
skeletal muscle, skin and bone
human fetal primary cells as a
function of time with 260 cells/
cm2 for each sample. Each data
point is represented by the
average cell number from three
culture plates. Bottom 5.1H11
and desmin
immunohistochemical staining
of fetal skeletal muscle, skin
and bone primary cell culture.
·50 magnification
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1 · 106 cells/ml with PBS ready to be used for injection
into recipient mice.
Cell survival in PBS
Cell viability of PKH26 marked fetal cells was assessed by
trypan blue exclusion (Sigma Chemicals). After PKH26
cell labeling, cells were left at room temperature, and
trypan blue cell exclusion was performed every 30 min
until 4 h and after 24 h. At each time point, a freshly
prepared solution of 10 ll trypan blue (0.05%) in distilled
water was mixed with 10 ll of cellular suspension for
5 min, and the cells were then counted with the aid of a
hemacytometer.
In vivo assessment of fetal myoblast cell injection
The animal study was approved by the local Ethics
Committee of the Lausanne University Hospital under
protocol #1585. Twelve-week-old male C57BL/6 mice
were obtained from Iffa Credo and were housed locally
for at least 1 week before the experimentation began.
Eleven mice were anesthetized (5 ll/mg mice of a mix
containing 500 ll Rampun, 2 ml, Ketalar and 2.5 ml
PBS). Left and right tibialis anterior muscles (TA) were
punched with a 21-gauge needle six times in a circular
fashion within 0.5 cm diameter to create an injury. The
center of the left injured TA muscle was injected with
5 · 104 PKH26 marked male fetal muscular cells in PBS
with a Hamilton syringe (Bonaduz, CH, USA). The center
of the right injured TA muscle was injected with vehicle
(PBS) as an internal control.
Five mice were killed 24 hours after the intervention
and 6 mice 4 days later. TA muscles were frozen in liquid
nitrogen-cooled isopentane and cryostat sectioned. Frozen
sections (6–10 lm) were DAPI stained to visualize nuclei
and were examined for the presence of PKH26 red fluo-
rochrome with an Olympus BX-40 microscope fitted with
appropriate filters. Other frozen sections were stained with
hematoxylin and eosin (H&E).
Nucleic acid extraction and reverse transcription
Total RNA was extracted from primary cell lines and
from twenty 25 lm sections of frozen mice TA muscles
tissue using the NucleoSpin, RNA II kit (NucleoSpin,
RNA II, Marchery-Nagel, Du¨ren, Germany) as described
by the manufacturer. RNA integrity was assessed on a
1% agarose gel.
Two micrograms of total RNA were reverse transcribed
using 50 U of StrataScript reverse transcriptase enzyme
(Stratagene, San Diego, CA, USA) in a volume of 50 ll
containing first strand buffer (Stratagene), 3 ll of random
primers (100 ng/ll), 40 U of RNasin (Promega, Madison,
WI, USA) and 2 ll of dNTP mix 100 mM (Promega), as
described by the manufacturer. The thermocycler Biome-
tra T-1 (Biomedizinische Analytik GmbH, Go¨ttingen,
Germany) was programmed as follows: 65C for 10 min,
37C for 60 min and 90C for 5 min.
Reverse transcriptase polymerase chain reaction
(RT-PCR)
Desmin cDNA fragment of 519 bp, actin cDNA fragment
of 739 bp and 18S cDNA fragment of 486 pb were ampli-
fied by RT-PCR using the primer sets as follows,
respectively: (Desmin) forward 50-CCTACTCTGCCCTCA
11H1.5
nimseD
Fig. 3 5.1H11 and desmin immunohistochemical staining of fetal
skeletal muscle primary cell culture after 5 years of cryopreservation.
·50 magnification
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ACTTC-30 and reverse 50-AGTATCCCAACACCCTGC
TC-30, (Actin) forward 50-GTTGCTATCCAGGCTGTG-30
and reverse 50-CATAGTCCGCCTAGAAGC-30, (18S)
forward 50-TTAAGCCATGCATGTCTAAGTAC-30 and
reverse 50- TGTTATTTTTCGTCACTACCTCC-30 with a
Biometra T-1 thermocycler (Biomedizinische Analytik
GmbH, Go¨ttingen, Germany) . After denaturation at 95C
for 5 min, 25 to 35 cycles of amplification were performed
as follows: 94C for 45 s, annealing temperature (Desmin:
65C; Actin: 60C; 18S: 55C) for 30 s, 72C for 30 s, and
finally an elongation of 72C for 15 min. PCR products
were electrophoresed together on a 2% agarose gel.
Results
Cell growth and expression of muscle markers in fetal
muscle cells
The growth of fetal muscle cells has been shown to be
much greater than that of cells from adult donors.
Although growth of fetal cells can be observed already in
the initial days after muscle fibers have been placed in
culture dishes, growth of adult muscle cells treated under
the same conditions usually starts only after 10–12 days.
Once cultures are established, fetal cells continue to grow
at a much faster rate than cells from adults (Fig. 1). The
analysis of cell number as a function of days in culture
when starting with a low number of cells (260 cell/cm2)
shows a sharp difference after 11 days of culture. This
difference in the growth rate is related to the age of the
donor.
In a simple culture medium, fetal muscle cells express a
higher density of muscle markers, such as desmin and
5.1H11, than that of young and adult cells cultivated under
the same conditions (Fig. 1).
When compared with fetal skin fibroblasts used in
clinics [45, 47] and bone-derived fetal cells (Fig. 2), it
appears that primary fetal cultures are tissue specific. Fetal
skin fibroblasts reach confluence earlier (after 9 days) than
muscle and bone fetal cells. Each primary cell line has a
specific growth capacity and only fetal muscle cells express
muscular markers (Fig. 2).
Human skeletal muscle fetal cells cryopreservation
After 5 years of liquid nitrogen storage, primary fetal
skeletal muscle cells were thawed and expanded;
immunohistochemistry was performed for the 5.1H11
and desmin muscular markers. Each of the fetal cell
lines showed almost the same quantity of cells express-
ing desmin and 5.1H11 as did the ones before long-term
conservation (Fig. 3 compared to Figs. 1, 2). Adult cells
(30 years) could not be expanded after 5 years of cryo-
preservation. Under the same conditions, young
(13 years) cells could be thawed and expanded but there
were fewer cells expressing desmin or 5.1H11 (data not
shown).
Survival of human fetal skeletal muscle cells in PBS
A certain number of hours can elapse between the time of
preparation of the cells and their implantation into hosts
in animal experiments or in hospitalized patients. We
monitored the death rate of cells kept at room temperature
in PBS, to estimate how long one could wait before
injection and still have a majority of live cells. Figure 4
shows more than 70% of fetal skeletal muscle cells still
alive after 4 h at room temperature in PBS. After 24 h,
more than 60% of the cells were alive and with the same
morphology.
In vivo assessment of fetal skeletal muscle injection
Human fetal cells marked with PKH26 were visible after
24 h in the five analyzed mice, and they were still clearly
observed at 4 days after the injection. No PHK26 labeled
cells were observed in any of the collateral TA muscles
(Fig. 5).
Hematoxylin and eosin (H&E) coloration was per-
formed on 10 lm sections slides of wounded mice TA
muscles (Fig. 6). Twenty-four hours after injury, wounded
sites had no more infiltrating cells at the site of human fetal
cell injection. At 4 days after injection mononucleated
cells (inflammatory cells and myoblasts) increased in
number as expected; again there is not much inflammation
in the injected site in comparison to the internal control
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Fig. 4 Cell viability of cells stored 24 h at room temperature in PBS.
Measurements were performed in triplicate with associated SD of the
mean
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injected with PBS. Regenerating fibers are observable in
both (left and right) TA muscles.
RNA was extracted from 20 tissue sections of 25 lm
thickness with Trizol. RNA was quantified by optic den-
sity. Fluorescence analysis was performed on a slide before
and after the 20 cryosections to ensure that human PKH26
marked cells were present. Amplification was accom-
plished for the human b-actin gene and for the mouse 18S
as a positive control for the RNA quality. Presence of
human b-actin RNA was observed in samples 1 and 4 days
after injection (Fig. 7). Presence of b-actin was only
observed in the left fetal cell treated TA muscle. It was not
possible to observe desmin expression by classic RT-PCR
in the samples.
Discussion
Herein, we investigate the possibility to create a human
primary fetal skeletal muscle cell bank that could be used
as a cell source for muscle cell therapy and tissue engi-
neering. To this purpose, we first analyzed the growth
capacity of fetal muscle cells compared to adult cells by
means of specific muscle markers. Then, we compared
fetal muscle cells to fetal skin and bone cells in vitro under
identical culture conditions to determine their lineage
specificity. We ensured that fetal muscular cells kept their
characteristics after long-term cryopreservation. Finally,
human fetal muscle cells were injected in normal C57BL/6
mice to assess survival after up to 4 days.
The proliferation rate of primary fetal muscle cells was
similar to that of fetal skin and fetal bone cells, but more
rapid than young and adult muscle donor cells. Moreover,
the growth rate of muscle cells was age-related as descri-
bed previously by Scha¨fer et al. [58]. Primary fetal muscle
cells showed a higher number of cells expressing desmin
than did young and adult derived muscle cells. Fetal
muscular cells were found to conserve their high desmin
counts after long-term cryopreservation. Scha¨fer et al.
demonstrate that when human muscle cultured cells
L d1R d1
R d4 L d4
U
Fig. 5 Right Fluorescence
analysis for the presence of
PKH26 (red) human fetal
skeletal muscular on mice left
and right TA muscle
cryosections. Nuclei are
counterstained with Dapi (blue).
At 1 day post-injection red
labeled cells are found in left
TA muscle (1d L) and not in the
right control TA muscle (1d R).
At 4 days after injection, red
labeled cells are found in left
TA muscle (4d L) and not in the
right control TA muscle (4d R).
U Uninjured muscle. ·100
magnification
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maintain their high desmin content or show little loss
during expansion in vitro, they produce more myogenic
than non-myogenic nuclei in vivo [59].
Cell delivery is an important aspect of cell therapy;
several hours can elapse from the laboratory to the clin-
ical application with fetal cells. We show that even after
24 h at room temperature in saline solution 60% of fetal
muscle cells are still viable. After 1 h results are com-
parable with other publications which show 93–97%
viability of the cells after 1 h on ice [60]. The reason for
the rapid death of injected myoblasts is still unclear;
immunological rejection was considered but the timing of
cellular death (1–48 h) combined with the fact that whole
muscle grafts in mice (uncultured cells) show good sur-
vival after 1 year argues against it [61]. These data
strongly suggest that myoblast isolation and culture can
have adverse effects on the survival of donor cells into in
vivo situation. On the other hand, Tambara et al. have
recently shown that neonatal skeletal myoblasts can fully
replace an infarcted myocardium when they survive in the
host in large number. When 5 · 107 skeletal neonatal
muscles cells were injected in infarcted rat hearts, a
reversion of LV remodeling was observed, whereas when
5 · 105 skeletal muscle cells were injected remodeling
R d1
L d4R d4
L d1
U
Fig. 6 Left TA muscle histology 1 and 4 days post-injection of
human fetal skeletal muscle cells. Fetal muscle injected left (L) and
vehicle injected right (R) TA muscle cryosections were H&E stained.
Uninjured muscle (U) shows a typical pattern of evenly sized
myofibers with peripheral nuclei. One day after injection, the needle
sectioned muscle is visible with little infiltrating mononuclear cells,
for left and right TA muscle (1d R and 1d L). At 4 days after injury
mononucleated cells (inflammatory cells and myoblasts) increase in
number, and appearance of new myotubes is observed for left and
right TA muscles (4d R and 4d L). ·100 magnification
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was inhibited [62]. The use of fetal cells may bypass these
inconveniences. In our study we can still observe human
fetal cells and human b-actin gene expression at 4 days
after injection in all the analyzed samples, indicating that
cells are still present in a sufficient quantity to detect
RNA even with a small amount of injected cells. Herein,
we have injected 5 · 104 human fetal muscular cells into
mice, when 5 to 100 times more cells are used in other
animal studies. Fetal cells are already differentiated as we
observe by immunohistochemistry with different fetal cell
types. This was also shown in vivo by Sakai et al. in a
study wherein three different fetal cell types (cardio-
myocytes, smooth muscle and skin fibroblasts) were used
to repair a myocardial scar in rats. Histological studies
after transplantation showed that the transplanted cells
formed a block of tissue composed of their specific cell
type in the myocardial scar [63]. Altogether, fetal skeletal
muscle cells show qualities required for the establishment
of a cell bank to be used for cell therapy. Fetal cells have
a higher potential of division before senescence because
of the longer telomeres in comparison to adult cells [64].
The rapid growth of the cells facilitates the creation of an
important cell bank starting from one donor as it was done
for fetal skin cells [55] (Fig. 8). With one organ donation
of 1 cm3, we would be able to generate more than
1.5 · 1012 cells at passage 4, and therefore we would
have the ability to make more than 28,000 injections with
7 · 107 cells as it was used in the clinics for human
Duchenne Muscular Dystrophic patients [65, 66]. For each
organ donation, the mother donors are tested for infectious
diseases (status of the donor for HIV, HBV and HCV) at
the time of tissue donation and again 3 months later to
assure negative sero-conversion [47]. Careful selection of
a donor and an extensive screening to avoid transmissible
viral, fungal or bacterial disease provide a safe and secure
utilization of fetal cells for therapeutic usage.
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Fig. 8 With one organ donation
of 1–2 cm3, it is possible to
establish a fetal muscle cell
bank that is potentially able to
produce more than 1.5 · 1012
cells for cellular therapy and
tissue engineering
H WUR L
1d
R L
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Fig. 7 RT-PCR amplification of human b-actin gene. 1d R Right TA
control muscle 1 day post-vehicle injection. 1d L Left TA muscle
1 day after human fetal skeletal muscle cell injection. U Unwounded
control mice, H Human, W Water
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